Incretin Biology: GLP-1, GIP & Glucagon in Metabolic Research

The most significant development in metabolic research over the past decade is the discovery of the incretin hormone system and the design of agonists targeting its receptors. GLP-1, GIP, and glucagon are not new—they were characterized decades ago—but their combined activation in single peptide molecules has transformed research into obesity and metabolic disease. This article explains the mechanisms behind these hormones and why dual and triple agonists have become central to 2026 research.

What Are Incretin Hormones?

Incretins are hormones released by intestinal cells within minutes of nutrient ingestion. Their job is to prepare the body to handle incoming glucose by stimulating insulin secretion and slowing gastric emptying. Two incretin hormones dominate the system:

• GLP-1 (Glucagon-Like Peptide-1): Secreted by L-cells in the distal ileum and colon in response to glucose and other nutrients.
• GIP (Glucose-Dependent Insulinotropic Polypeptide): Secreted by K-cells in the proximal small intestine, responding primarily to glucose and fat.

Together, they account for 50–70% of the total postprandial (after-meal) insulin secretion in a healthy person. This is why agonizing their receptors has such profound metabolic effects.

GLP-1 Receptor Signaling

GLP-1 acts through the GLP-1 receptor (GLP-1R), a seven-transmembrane G-protein-coupled receptor expressed on pancreatic β-cells, neurons, and other tissues. Activation triggers:

• Glucose-dependent insulin secretion: GLP-1 stimulates β-cells only when blood glucose is elevated—not when it is low. This is crucial: it means GLP-1 agonists lower glucose without causing hypoglycemia.
• Slowed gastric emptying: Food moves from the stomach to the intestine more slowly, allowing more time for nutrient absorption and preventing glucose spikes.
• Satiety signaling: GLP-1 acts on the brainstem to promote feeling of fullness, reducing hunger and food intake—a mechanism that drives weight loss in preclinical models.
• β-cell proliferation and apoptosis resistance: Chronic GLP-1 activation promotes survival of insulin-producing cells and may regenerate β-cell mass (preclinical evidence).

GIP Receptor Signaling

GIP also acts through a GPCR (GIP receptor, formerly called GIPR). Its effects include:

• Synergistic insulin secretion: GIP amplifies the insulin-secreting effect of GLP-1 when both are present simultaneously.
• Inhibition of glucagon: Reduces the counter-regulatory hormone that raises blood glucose.
• Adipose tissue effects: GIP promotes energy storage but, importantly, dual GIP/GLP-1 agonists show reduced fat deposition compared to GLP-1 alone—a surprising mechanistic finding of 2024–2026 research.
• Bone formation: GIP stimulates osteoblasts and may improve bone health—preclinical evidence suggests potential benefits beyond glucose control.

Glucagon Receptor Signaling in Triple Agonists

The newest frontier is triple agonists—single molecules that activate GLP-1, GIP, and glucagon receptors simultaneously. Glucagon, normally a counter-regulatory hormone that raises blood glucose, has an unexpected role when combined with GLP-1/GIP:

• Hepatic energy expenditure: Glucagon receptor activation promotes fat oxidation in the liver, contributing to weight loss beyond appetite suppression alone.
• Reduced hepatic glucose production: The net effect is still glucose-lowering because the insulin secretion from GLP-1/GIP dominates when glucose is high.
• Hepatic lipid reduction: Triple agonists show unprecedented reductions in liver fat—up to 82% in Phase 2 trials—offering potential benefit in NASH and metabolic dysfunction-associated fatty liver disease.

The discovery that adding glucagon activation to GIP/GLP-1 agonism did not cause problematic hyperglycemia was a major 2024–2025 breakthrough, enabling retatrutide and similar compounds.

Shared Effects: Why These Hormones Work Together

Glucose-dependent insulin secretion: Both GLP-1 and GIP are glucose-dependent, meaning they only trigger insulin release when blood glucose is high enough to warrant it. This safety feature is why agonists carry a lower hypoglycemia risk than older insulin secretagogues.

Synergistic β-cell effects: GLP-1 and GIP have overlapping downstream signaling—cAMP elevation, PKA activation, MAPK pathways—and when both act together, the effects are greater than either alone.

Why This Matters to 2026 Research

Understanding incretin biology is foundational to evaluating metabolic peptides. Whether you are studying GLP-1 agonists, dual GIP/GLP-1 compounds, or triple agonists, the underlying mechanism traces back to these hormone-receptor interactions. Publications that cite incretin signaling pathways are more credible and more publishable than those that do not ground their work in this established physiology.

Research metabolic peptides

Browse metabolic research peptides

Sources & further reading

• MDPI — The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health
• Gastroenterology — Biology of Incretins: GLP-1 and GIP
• NIH — Mechanisms of Action and Therapeutic Applications of GLP-1 and Dual GIP/GLP-1 Receptor Agonists

Universe Peptide publishes research-focused education for the scientific community. Products are for laboratory research only. See more in our News & research updates.